Brilliant Violet 421™ anti-human IFN-γ

Antibodies Single
Sony
B27
Intracellular Flow Cytometry
Mouse IgG1, κ
Human,Non-human primate,Other
E. coli-expressed recombinant human IFN-γ
3132690
$355.00

Description

Interferon-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells. The B27 antibody reacts with the human interferon-γ. The B27 antibody can neutralize the bioactivity of natural or recombinant IFN-γ.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.



This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

  1. Favre C, et al. 1989. Molec. Immunol. 26:17. (Neut)
  2. Kaur A, et al. 2002. J Virol. 76:3646.
  3. Abrams J, et al. 1992. Immunol. Rev. 127:5. (Neut)
  4. Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag.
  5. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  6. Acosta-Rodriguez EV, et al. 2007. Nat. Immunol. 9:942-9. (Neut)
  7. Gangur V, et al. 1998. FASEB J. 12:705-13. (Neut)